Now showing items 2077-2096 of 3378

    • Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. 

      Ferris, RL; Blumenschein, G; Fayette, J; Guigay, J; Colevas, AD; Licitra, L; Harrington, K; Kasper, S; Vokes, EE; Even, C; Worden, F; Saba, NF; Iglesias Docampo, LC; Haddad, R; Rordorf, T; Kiyota, N; Tahara, M; Monga, M; Lynch, M; Geese, WJ; Kopit, J; Shaw, JW; Gillison, ML (2016-11)
      BACKGROUND:Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum chemotherapy have a very poor prognosis and limited therapeutic options. Nivolumab, an anti-programmed death 1 ...
    • Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. 

      Harrington, KJ; Ferris, RL; Blumenschein, G; Colevas, AD; Fayette, J; Licitra, L; Kasper, S; Even, C; Vokes, EE; Worden, F; Saba, NF; Kiyota, N; Haddad, R; Tahara, M; Grünwald, V; Shaw, JW; Monga, M; Lynch, M; Taylor, F; DeRosa, M; Morrissey, L; Cocks, K; Gillison, ML; Guigay, J (2017-08)
      BACKGROUND:Patients with platinum-refractory recurrent or metastatic squamous cell carcinoma of the head and neck have few treatment options and poor prognosis. Nivolumab significantly improved survival of this patient ...
    • Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. 

      Ferris, RL; Blumenschein, G; Fayette, J; Guigay, J; Colevas, AD; Licitra, L; Harrington, KJ; Kasper, S; Vokes, EE; Even, C; Worden, F; Saba, NF; Docampo, LCI; Haddad, R; Rordorf, T; Kiyota, N; Tahara, M; Lynch, M; Jayaprakash, V; Li, L; Gillison, ML (2018-06)
      OBJECTIVES:We report 2-year results from CheckMate 141 to establish the long-term efficacy and safety profile of nivolumab and outcomes by tumor PD-L1 expression in patients with recurrent or metastatic (R/M),platinum-refractory ...
    • No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. 

      Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2; Hollestelle, A; van der Baan, FH; Berchuck, A; Johnatty, SE; Aben, KK; Agnarsson, BA; Aittomäki, K; Alducci, E; Andrulis, IL; Anton-Culver, H; Antonenkova, NN; Antoniou, AC; Apicella, C; Arndt, V; Arnold, N; Arun, BK; Arver, B; Ashworth, A; Australian Ovarian Cancer Study Group; Baglietto, L; Balleine, R; Bandera, EV; Barrowdale, D; Bean, YT; Beckmann, L; Beckmann, MW; Benitez, J; Berger, A; Berger, R; Beuselinck, B; Bisogna, M; Bjorge, L; Blomqvist, C; Bogdanova, NV; Bojesen, A; Bojesen, SE; Bolla, MK; Bonanni, B; Brand, JS; Brauch, H; Breast Cancer Family Register; Brenner, H; Brinton, L; Brooks-Wilson, A; Bruinsma, F; Brunet, J; Brüning, T; Budzilowska, A; Bunker, CH; Burwinkel, B; Butzow, R; Buys, SS; Caligo, MA; Campbell, I; Carter, J; Chang-Claude, J; Chanock, SJ; Claes, KBM; Collée, JM; Cook, LS; Couch, FJ; Cox, A; Cramer, D; Cross, SS; Cunningham, JM; Cybulski, C; Czene, K; Damiola, F; Dansonka-Mieszkowska, A; Darabi, H; de la Hoya, M; deFazio, A; Dennis, J; Devilee, P; Dicks, EM; Diez, O; Doherty, JA; Domchek, SM; Dorfling, CM; Dörk, T; Silva, IDS; du Bois, A; Dumont, M; Dunning, AM; Duran, M; Easton, DF; Eccles, D; Edwards, RP; Ehrencrona, H; Ejlertsen, B; Ekici, AB; Ellis, SD; EMBRACE; Engel, C; Eriksson, M; Fasching, PA; Feliubadalo, L; Figueroa, J; Flesch-Janys, D; Fletcher, O; Fontaine, A; Fortuzzi, S; Fostira, F; Fridley, BL; Friebel, T; Friedman, E; Friel, G; Frost, D; Garber, J; García-Closas, M; Gayther, SA; GEMO Study Collaborators; GENICA Network; Gentry-Maharaj, A; Gerdes, A-M; Giles, GG; Glasspool, R; Glendon, G; Godwin, AK; Goodman, MT; Gore, M; Greene, MH; Grip, M; Gronwald, J; Gschwantler Kaulich, D; Guénel, P; Guzman, SR; Haeberle, L; Haiman, CA; Hall, P; Halverson, SL; Hamann, U; Hansen, TVO; Harter, P; Hartikainen, JM; Healey, S; HEBON; Hein, A; Heitz, F; Henderson, BE; Herzog, J; T Hildebrandt, MA; Høgdall, CK; Høgdall, E; Hogervorst, FBL; Hopper, JL; Humphreys, K; Huzarski, T; Imyanitov, EN; Isaacs, C; Jakubowska, A; Janavicius, R; Jaworska, K; Jensen, A; Jensen, UB; Johnson, N; Jukkola-Vuorinen, A; Kabisch, M; Karlan, BY; Kataja, V; Kauff, N; KConFab Investigators; Kelemen, LE; Kerin, MJ; Kiemeney, LA; Kjaer, SK; Knight, JA; Knol-Bout, JP; Konstantopoulou, I; Kosma, V-M; Krakstad, C; Kristensen, V; Kuchenbaecker, KB; Kupryjanczyk, J; Laitman, Y; Lambrechts, D; Lambrechts, S; Larson, MC; Lasa, A; Laurent-Puig, P; Lazaro, C; Le, ND; Le Marchand, L; Leminen, A; Lester, J; Levine, DA; Li, J; Liang, D; Lindblom, A; Lindor, N; Lissowska, J; Long, J; Lu, KH; Lubinski, J; Lundvall, L; Lurie, G; Mai, PL; Mannermaa, A; Margolin, S; Mariette, F; Marme, F; Martens, JWM; Massuger, LFAG; Maugard, C; Mazoyer, S; McGuffog, L; McGuire, V; McLean, C; McNeish, I; Meindl, A; Menegaux, F; Menéndez, P; Menkiszak, J; Menon, U; Mensenkamp, AR; Miller, N; Milne, RL; Modugno, F; Montagna, M; Moysich, KB; Müller, H; Mulligan, AM; Muranen, TA; Narod, SA; Nathanson, KL; Ness, RB; Neuhausen, SL; Nevanlinna, H; Neven, P; Nielsen, FC; Nielsen, SF; Nordestgaard, BG; Nussbaum, RL; Odunsi, K; Offit, K; Olah, E; Olopade, OI; Olson, JE; Olson, SH; Oosterwijk, JC; Orlow, I; Orr, N; Orsulic, S; Osorio, A; Ottini, L; Paul, J; Pearce, CL; Pedersen, IS; Peissel, B; Pejovic, T; Pelttari, LM; Perkins, J; Permuth-Wey, J; Peterlongo, P; Peto, J; Phelan, CM; Phillips, K-A; Piedmonte, M; Pike, MC; Platte, R; Plisiecka-Halasa, J; Poole, EM; Poppe, B; Pylkäs, K; Radice, P; Ramus, SJ; Rebbeck, TR; Reed, MWR; Rennert, G; Risch, HA; Robson, M; Rodriguez, GC; Romero, A; Rossing, MA; Rothstein, JH; Rudolph, A; Runnebaum, I; Salani, R; Salvesen, HB; Sawyer, EJ; Schildkraut, JM; Schmidt, MK; Schmutzler, RK; Schneeweiss, A; Schoemaker, MJ; Schrauder, MG; Schumacher, F; Schwaab, I; Scuvera, G; Sellers, TA; Severi, G; Seynaeve, CM; Shah, M; Shrubsole, M; Siddiqui, N; Sieh, W; Simard, J; Singer, CF; Sinilnikova, OM; Smeets, D; Sohn, C; Soller, M; Song, H; Soucy, P; Southey, MC; Stegmaier, C; Stoppa-Lyonnet, D; Sucheston, L; SWE-BRCA; Swerdlow, A; Tangen, IL; Tea, M-K; Teixeira, MR; Terry, KL; Terry, MB; Thomassen, M; Thompson, PJ; Tihomirova, L; Tischkowitz, M; Toland, AE; Tollenaar, RAEM; Tomlinson, I; Torres, D; Truong, T; Tsimiklis, H; Tung, N; Tworoger, SS; Tyrer, JP; Vachon, CM; Van 't Veer, LJ; van Altena, AM; Van Asperen, CJ; van den Berg, D; van den Ouweland, AMW; van Doorn, HC; Van Nieuwenhuysen, E; van Rensburg, EJ; Vergote, I; Verhoef, S; Vierkant, RA; Vijai, J; Vitonis, AF; von Wachenfeldt, A; Walsh, C; Wang, Q; Wang-Gohrke, S; Wappenschmidt, B; Weischer, M; Weitzel, JN; Weltens, C; Wentzensen, N; Whittemore, AS; Wilkens, LR; Winqvist, R; Wu, AH; Wu, X; Yang, HP; Zaffaroni, D; Pilar Zamora, M; Zheng, W; Ziogas, A; Chenevix-Trench, G; Pharoah, PDP; Rookus, MA; Hooning, MJ; Goode, EL (2016-05)
      OBJECTIVE:Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3' UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer ...
    • No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing. 

      Easton, DF; Lesueur, F; Decker, B; Michailidou, K; Li, J; Allen, J; Luccarini, C; Pooley, KA; Shah, M; Bolla, MK; Wang, Q; Dennis, J; Ahmad, J; Thompson, ER; Damiola, F; Pertesi, M; Voegele, C; Mebirouk, N; Robinot, N; Durand, G; Forey, N; Luben, RN; Ahmed, S; Aittomäki, K; Anton-Culver, H; Arndt, V; Australian Ovarian Cancer Study Group; Baynes, C; Beckman, MW; Benitez, J; Van Den Berg, D; Blot, WJ; Bogdanova, NV; Bojesen, SE; Brenner, H; Chang-Claude, J; Chia, KS; Choi, J-Y; Conroy, DM; Cox, A; Cross, SS; Czene, K; Darabi, H; Devilee, P; Eriksson, M; Fasching, PA; Figueroa, J; Flyger, H; Fostira, F; García-Closas, M; Giles, GG; Glendon, G; González-Neira, A; Guénel, P; Haiman, CA; Hall, P; Hart, SN; Hartman, M; Hooning, MJ; Hsiung, C-N; Ito, H; Jakubowska, A; James, PA; John, EM; Johnson, N; Jones, M; Kabisch, M; Kang, D; kConFab Investigators; Kosma, V-M; Kristensen, V; Lambrechts, D; Li, N; Lifepool Investigators; Lindblom, A; Long, J; Lophatananon, A; Lubinski, J; Mannermaa, A; Manoukian, S; Margolin, S; Matsuo, K; Meindl, A; Mitchell, G; Muir, K; NBCS Investigators; Nevelsteen, I; van den Ouweland, A; Peterlongo, P; Phuah, SY; Pylkäs, K; Rowley, SM; Sangrajrang, S; Schmutzler, RK; Shen, C-Y; Shu, X-O; Southey, MC; Surowy, H; Swerdlow, A; Teo, SH; Tollenaar, RAEM; Tomlinson, I; Torres, D; Truong, T; Vachon, C; Verhoef, S; Wong-Brown, M; Zheng, W; Zheng, Y; Nevanlinna, H; Scott, RJ; Andrulis, IL; Wu, AH; Hopper, JL; Couch, FJ; Winqvist, R; Burwinkel, B; Sawyer, EJ; Schmidt, MK; Rudolph, A; Dörk, T; Brauch, H; Hamann, U; Neuhausen, SL; Milne, RL; Fletcher, O; Pharoah, PDP; Campbell, IG; Dunning, AM; Le Calvez-Kelm, F; Goldgar, DE; Tavtigian, SV; Chenevix-Trench, G (2016-05)
      BACKGROUND:BRCA1 interacting protein C-terminal helicase 1 (BRIP1) is one of the Fanconi Anaemia Complementation (FANC) group family of DNA repair proteins. Biallelic mutations in BRIP1 are responsible for FANC group J, ...
    • NON-CODING NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKAEMIA; THEIR CLINICAL IMPACT IN THE CLL4 CLINICAL TRIAL 

      Larrayoz, M; Rose-Zerilli, MJ; Parker, H; Blakemore, SJ; Forster, J; Davis, Z; Steele, AJ; Else, M; Catovsky, D; Oscier, DG; Strefford, JC (2016-06)
    • Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors. 

      Hahne, JC; Valeri, N (2018-01)
      Non-coding RNAs are important regulators of gene expression and transcription. It is well established that impaired non-coding RNA expression especially the one of long non-coding RNAs and microRNAs is involved in a number ...
    • The non-coding variant rs1800734 enhances DCLK3 expression through long-range interaction and promotes colorectal cancer progression. 

      Liu, NQ; Ter Huurne, M; Nguyen, LN; Peng, T; Wang, S-Y; Studd, JB; Joshi, O; Ongen, H; Bramsen, JB; Yan, J; Andersen, CL; Taipale, J; Dermitzakis, ET; Houlston, RS; Hubner, NC; Stunnenberg, HG (2017-02-14)
      Genome-wide association studies have identified a great number of non-coding risk variants for colorectal cancer (CRC). To date, the majority of these variants have not been functionally studied. Identification of ...
    • Non-coplanar trajectories to improve organ at risk sparing in volumetric modulated arc therapy for primary brain tumors. 

      Smyth, G; Evans, PM; Bamber, JC; Mandeville, HC; Welsh, LC; Saran, FH; Bedford, JL (2016-10)
      To evaluate non-coplanar volumetric modulated arc radiotherapy (VMAT) trajectories for organ at risk (OAR) sparing in primary brain tumor radiotherapy.Fifteen patients were planned using coplanar VMAT and compared against ...
    • Non-Invasive Prostate Cancer Characterization with Diffusion-Weighted MRI: Insight from In silico Studies of a Transgenic Mouse Model. 

      Hill, DK; Heindl, A; Zormpas-Petridis, K; Collins, DJ; Euceda, LR; Rodrigues, DN; Moestue, SA; Jamin, Y; Koh, D-M; Yuan, Y; Bathen, TF; Leach, MO; Blackledge, MD (2017-01)
      Diffusion-weighted magnetic resonance imaging (DWI) enables non-invasive, quantitative staging of prostate cancer via measurement of the apparent diffusion coefficient (ADC) of water within tissues. In cancer, more advanced ...
    • Non-Mono-Exponential Analysis of Diffusion-Weighted Imaging for Treatment Monitoring in Prostate Cancer Bone Metastases. 

      Reischauer, C; Patzwahl, R; Koh, D-M; Froehlich, JM; Gutzeit, A (2017-07-19)
      Diffusion-weighted imaging quantified using the mono-exponential model has shown great promise for monitoring treatment response in prostate cancer bone metastases. The aim of this prospective study is to evaluate whether ...
    • Noncoding RNA in Cholangiocarcinoma. 

      Salati, M; Braconi, C (2019-02)
      Cholangiocarcinomas (CCAs) are tumors with a dismal prognosis. Early diagnosis is a key challenge because of the lack of specific symptoms, and the curability rate is low due to the difficulty in achieving a radical resection ...
    • Noncoding RNAs as novel biomarkers in pancreatic cancer: what do we know? 

      Previdi, MC; Carotenuto, P; Zito, D; Pandolfo, R; Braconi, C (2017-02)
      Pancreatic cancer is an aggressive cancer of the digestive system, which is becoming a serious health problem worldwide. Overall survival for patients with pancreatic cancer is poor, mainly due to a lack of biomarkers to ...
    • A noninterventional, multicenter, prospective phase IV study of trabectedin in patients with advanced soft tissue sarcoma 

      Buonadonna, A; Benson, C; Casanova, J; Kasper, B; López Pousa, A; Mazzeo, F; Brodowicz, T; Penel, N (Ovid Technologies (Wolters Kluwer Health), 2017-11)
    • Noninvasive detection of carboxypeptidase G2 activity in vivo. 

      Jamin, Y; Smyth, L; Robinson, SP; Poon, ESC; Eykyn, TR; Springer, CJ; Leach, MO; Payne, GS (2011-05)
      The pseudomonad protein, carboxypeptidase G2 (CPG2), is a prodrug-activating enzyme utilized in the targeted chemotherapy strategies of antibody- and gene-directed enzyme prodrug therapy (ADEPT and GDEPT). We have developed ...
    • Noninvasive detection of HER2 amplification with plasma DNA digital PCR. 

      Gevensleben, H; Garcia-Murillas, I; Graeser, MK; Schiavon, G; Osin, P; Parton, M; Smith, IE; Ashworth, A; Turner, NC (2013-06)
      PURPOSE:Digital PCR is a highly accurate method of determining DNA concentration. We adapted digital PCR to determine the presence of oncogenic amplification through noninvasive analysis of circulating free plasma DNA and ...
    • Noninvasive high-intensity focused ultrasound treatment of twin-twin transfusion syndrome: A preliminary in vivo study. 

      Shaw, CJ; Civale, J; Botting, KJ; Niu, Y; Ter Haar, G; Rivens, I; Giussani, DA; Lees, CC (2016-07)
      We investigated the efficacy, maternofetal responses, and safety of using high-intensity focused ultrasound (HIFU) for noninvasive occlusion of placental vasculature compared to sham treatment in anesthetized pregnant ...
    • Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI. 

      Panek, R; Welsh, L; Baker, LCJ; Schmidt, MA; Wong, KH; Riddell, AM; Koh, D-M; Dunlop, A; Mcquaid, D; d'Arcy, JA; Bhide, SA; Harrington, KJ; Nutting, CM; Hopkinson, G; Richardson, C; Box, C; Eccles, SA; Leach, MO; Robinson, SP; Newbold, KL (2017-08)
      Purpose: To evaluate intrinsic susceptibility (IS) MRI for the identification of cycling hypoxia, and the assessment of its extent and spatial distribution, in head and neck squamous cell carcinoma (HNSCC) xenografts and ...